BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine

BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine

January 8, 2013

BIND Biosciences and Amgen Sign Agreement for the Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

Collaboration to Develop a Novel and Targeted Accurin™ Based on BIND’s Nanomedicine Platform and Amgen’s Kinase Inhibitor

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis

January 4, 2013

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC).

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

January 2, 2013

Moderna Therapeutics Announces Appointment Of Stephen Hoge, MD As Senior Vice President Of Corporate Development And New Drug Concepts

Moderna Therapeutics Announces Appointment Of Stephen Hoge, MD As Senior Vice President Of Corporate Development And New Drug Concepts

December 19, 2012

CAMBRIDGE, Mass., Dec. 19, 2012 /PRNewswire via COMTEX/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Stephen Hoge, MD, currently a partner at McKinsey & Company, will join the company as Senior Vice President of Corporate Development and New Drug Concepts on January 1st, 2013. In this newly created role, Dr.

Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

December 18, 2012

Pharmaceutical industry leader to drive company growth and strategy with initial focus on new classes of cancer therapies

Blend Therapeutics Closes $16 Million in Series B Financing

Blend Therapeutics Closes $16 Million in Series B Financing

December 18, 2012

Company accelerates product development with two lead programs

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

December 11, 2012

Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013

Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease

Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically-delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease

December 10, 2012

Follows Successful Completion of Phase 1a Clinical Study

Lead Candidate from Eleven’s AMP-Rx Product Engine for First-of-a-Kind Protein Therapeutics

T2 Biosystems Presents Data on Rapid and Direct Hemostasis Monitoring at ASH 2012

T2 Biosystems Presents Data on Rapid and Direct Hemostasis Monitoring at ASH 2012

December 10, 2012

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on T2Hemostasis, the first system capable of rapidly characterizing key coagulation, platelet and other hematologic factors directly from whole blood on a single, compact instrument. The data were presented by researchers from the University of Pennsylvania at the 54th Annual Meeting of the American Society for Hematology (ASH) in Atlanta, GA.

Moderna Announces $40 Million In Financing To Advance Development Of New Biotherapeutic Modality: Messenger RNA Therapeutics™

Moderna Announces $40 Million In Financing To Advance Development Of New Biotherapeutic Modality: Messenger RNA Therapeutics™

December 6, 2012
Company announces appointment of Executive Leadership Team and Scientific Advisory Board